

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 13-11-2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 11-8-2007 TO BE PUBLISHED ON 14-11-2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

940/2007	<u>06-08-2007</u> Cypress Bioscience, Inc. USA (Priority 09-8-06 USA)	“Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome”
941/2007	Syngenta Participations AG, Switzerland (Priority 08-8-06 Europe)	“Process for the production of amines”
942/2007	Cypress Bioscience, Inc. USA (Priority 09-8-06 USA)	“Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia”
943/2007	Sanofi-Aventis France (Priority 08-8-06 Germany)	“Arylaminoarylalkyl-substituted imidazolidine-2,4-diones, process for their preparation, medicaments comprising these compounds and use thereof”
944/2007	<u>07-8-2007</u> Millennium Pharmaceuticals, Inc. USA (Priority 08-8-06 US)	“Heteroaryl compounds useful as inhibitors of E1 activating enzymes”
945/2007	AstraZeneca AB, Sweden (Priority 17-8-06 USA)	“Chemical compounds”
946/2007	AstraZeneca AB, Sweden (Priority 17-8-06 USA)	“Chemical compounds”
947/2007	SmithKline Beecham Corporation USA (Priority 09-8-06 US)	“Pyrrolidinone anilines as progesterone receptor modulators”
948/2007	<u>08-8-2007</u> Unilever Plc, England (Priority 23-8-06 India)	“Tea composition”
949/2007	KEMIA, Inc. USA (Priority 17-8-06 USA)	“Heteroaryl derivatives as cytokine inhibitors”
950/2007	Deere & Company USA (Priority 19-10-06 US)	“Drawn cotton picker”

951/2007	Glaxo Group Limited, United Kingdom (Priority 10-8-06 GB)	“Novel compounds”
952/2007	Sanofi-Aventis France (Priority 11-8-06 France)	“Derivatives of 5,6-bisaryl-2-pyridine-carboxamide, their preparation and their application in therapeutics as antagonists of urotensin II receptors”
953/2007	<u>09-8-2007</u> Bristol-Myers Squibb Company, USA (Priority 09-8-06 USA)	“Modulators of glucocorticoid receptor, AP-1, and/or nf-kB activity and use thereof”
954/2007	Bristol-Myers Squibb Company, USA (Priority 09-8-06 USA)	“Hepatitis virus inhibitors”
955/2005	Infinity Discovery, Inc. USA (Priority 21-8-06 US)	“Compounds and methods for inhibiting the interaction of bcl proteins with binding partners”
956/2007	AstraZeneca AB Sweden (Priority 11-8-06 US)	“New benzimidazole derivatives 290”
957/2007	GlaxoSmithKline Consumer Healthcare GmbH & Co. KG, Germany (Priority 11-8-06 GB)	“Toothbrush”
958/2007	<u>10-8-2007</u> Eli Lilly and Company, USA (Priority 20-9-06 US)	“Thiazole pyrazolopyrimidine compounds”
959/2007	CIPLA Ltd, India (Priority 10-8-06 India)	“Antiretroviral solid oral composition”
960/2007	<u>11-8-2007</u> Momentive Performance Materials Inc. USA (Priority 14-8-06 USA)	“Rubber composition and articles flowing there from both comprising mercapto-functional silane”
961/2007	Momentive Performance Materials Inc. USA (Priority 14-8-06 USA)	“Free flowing filler composition comprising mercapto-functional silane”
962/2007	Momentive Performance Materials Inc. USA (Priority 14-8-06 USA)	“Process for making mercapto-functional silane”

963/2007	Momentive Performance Materials Inc. USA (Priority 14-8-06 USA)	“mercapto-functional silane”
964/2007	Genentech, Inc. USA (Priority 29-8-06 USA)	“Method treating stroke with thrombolytic agent”
965/2007	Sanofi-Aventis France (Priority 07-9-06 EP)	“Aqueous formulation comprising an antitumor agent”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

789/1999 Pfizer Products Inc.
USA

“4-amino
substituted-2-substituted-1,2,3,4-tetrahydroquinoline”

(CO7D, 215/18)

139286

Cholesteryl ester transfer protein inhibitor
pharmaceutical containing such inhibitor to elevate
certain plasma lipid levels, including high density
lipoprotein-cholesterol and to lower certain other
plasma lipid levels, such as LDL-cholesterol and
triglycerides and accordingly to treat diseases which
are exacerbated by low levels of HDL cholesterol
and/or high levels of LDL-cholesterol and
triglycerides, such as atherosclerosis and
cardiovascular diseases in some mammals, including
humans.

413/2004 Pfizer Products Inc.
USA

“Azithromycin with reduced side effects”

(INT: CL: A61K, 9/14)

139287

A Composition in an oral dosage form comprising
azithromycin and an effective amount of an alkalizing
agent. Preferably, said oral dosage form comprises an
effective amount of an alkalizing agent and an
azithromycin multiparticulate wherein said

multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral /suspension, a unit dose packet or sachet, a tablet or a capsule-

† Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer.

Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent.

Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.

Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable

carrier.

46/2005 ENI S.p.A. and
Enitecnologie S.p.A.
Italy

“Process for the removal of hydrogen sulfide, by means of its oxidation in the presence of hetero polyacids”

(CO1B, 17/16)

139288

Hydrogen sulfide is oxidized to sulfur by means of treatment with an aqueous acid solution containing trivalent iron and a hetero polyacid having formula (I):



or a sole hetero polyacid having formula (II): $H_n M_e M_{i_2} O_{40}; 5$ wherein the symbols X, M, M_e and y are specified in the text. At the end of the oxidation, the solution is treated with gas containing oxygen to re-oxidize the reduced metal.

50/2005 Danisco A/S.
Denmark

“Baked product with increased shelf life”

(INT: CL: A21D 13/08)

139289

The present invention relates to a non yeast-leavened fine bakery product with increased shelf life and to a process for increasing the shelf life of intermediate and high moisture fine bakery products. The fine bakery product comprises an intermediate or high moisture baked product having a water activity $a_w > 0.8$. its surface has deposited thereon an effective amount of natamycin, which is sufficient to keep the product mould free when packaged for a storage time of 2 weeks or more at ambient temperature. In the process the outer surface of baked product is sprayed with natamycin to deposit an effective amount of natamycin thereon, where after the sprayed product is packaged in a protective envelope.

608/2005 1. Dr. Muhammad Iqbal
2. Mr. Muhammad Younis
Faisalabad, Pakistan

“An improved boom sprayer for crops”

(AOIC: 23/04)

139290

This invention relates to a University Boom Sprayer. The sprayer is useful for spraying the crops. It has proved to be working satisfactorily. The sprayer of the present invention has the following salient features which are its characteristics features. Its nozzle can rotate and can spray over and under the leaves. Insect mortality while using this type of sprayer is 100%. The environmental pollution while using a sprayer of the present invention is negligible. As the last but quite important factor the cost of a product of the present invention is comparatively low.

609/2005 1. Dr. Muhammad Iqbal
2. Mr. Muhammad Younis
Faisalabad, Pakistan

“A boom sprayer test bench ”

(AOIC: 23/04)

139291

The invention relates to a test bench invented and developed by the inventors to evaluate different types of nozzles for their discharge, swath width, cone angle and spray pattern. The spray test bench frame made of angle iron decreased the initial cost of the machine. It has sufficient stiffness/strength to carry the load of corrugated sheet, boom assembly, two electric motors,

pump and other parts. The system checked practically proved to be efficient and reliable.